       Document 0755
 DOCN  M9640755
 TI    Differences in participation in experimental drug trials among persons
       with AIDS.
 DT    9604
 AU    Diaz T; Chu SY; Sorvillo F; Mokotoff E; Davidson AJ; Samuel MC; Herr M;
       Doyle B; Frederick M; Fann SA; et al; Division of HIV/AIDS, Centers for
       Disease Control and Prevention,; Atlanta, GA 30333, USA.
 SO    J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Dec 15;10(5):562-8.
       Unique Identifier : AIDSLINE MED/96142219
 AB    To measure participation in experimental drug trials among persons with
       acquired immunodeficiency syndrome (AIDS), we interviewed 4,604 persons
       at least 18 years of age who were reported to have AIDS to 11 state and
       city health departments in the United States. Ten percent reported that
       they were currently in a trial. Current enrollment differed
       significantly (p < 0.05) by race/ethnicity (blacks, 5%; whites, 14%;
       Hispanics, 15%), gender (women, 7%; men, 11%), exposure mode (injection
       drug use, 5%, men who have sex with men, 14%), annual household income
       (< $10,000, 8%, > or = $10,000, 14%), education (< 12 years, 6%; > or =
       12 years, 12%), health care (no regular care, 1%, public care, 8%;
       private care, 17%), and time since AIDS diagnosis (< or = 6 months, 9%;
       > 6 months, 12%). Adjusting for all factors and time since AIDS
       diagnosis, blacks (adjusted odds ratio [AOR] = 0.35, 95% confidence
       interval [CI] 0.26, 0.47), persons with less than 12 years of education
       (AOR = 0.71, CI 0.53, 0.96), and those without regular health care (AOR
       = 0.24, CI 0.10, 0.61) remained less likely to be in a trial. Blacks,
       those with less than 12 years of education, and persons without regular
       health care were less likely than other persons with AIDS to be
       currently enrolled in AIDS trials. To increase enrollment of these
       persons, researchers must address barriers to participation for these
       groups.
 DE    Acquired Immunodeficiency Syndrome/*DRUG THERAPY/EPIDEMIOLOGY
       Adolescence  Adult  Antiviral Agents/*THERAPEUTIC USE  Clinical
       Trials/*STATISTICS & NUMER DATA  Ethnic Groups  Female  Human  Male
       Patient Participation/*STATISTICS & NUMER DATA  Socioeconomic Factors
       United States/EPIDEMIOLOGY  JOURNAL ARTICLE  MULTICENTER STUDY

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

